Mitiglinide-d5 (calcium)

Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel) . Mitiglinide can be used for the research of type 2 diabetes[1][2].

Product Specifications

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Potassium Channel

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Solubility

10 mM in DMSO

Smiles

O=C(N1C[C@@](CCCC2)([H])[C@@]2([H])C1)C[C@@H](C([O-])=O)CC3=C([2H])C([2H])=C([2H])C([2H])=C3[2H].[Ca+2].[1/2]

Molecular Formula

C19H19D5NO3.1/2Ca

Molecular Weight

339.48

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29 (5-6) :423-7.|[3]Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431 (1) :119-25.